Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
The affiliation of the corresponding author Silvio Danese, which currently reads. (Source: Drugs)
Source: Drugs - June 2, 2020 Category: Drugs & Pharmacology Source Type: research

Correction to: Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma
The title for the dosage on line 3, which previously read. (Source: Drugs)
Source: Drugs - May 30, 2020 Category: Drugs & Pharmacology Source Type: research

Pemigatinib: First Approval
This article summarizes the milestones in the development of pemigatinib leading to this first approval for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma and a FGFR 2 fusion or other rearrangement, as detected by a US FDA-approved test. (Source: Drugs)
Source: Drugs - May 29, 2020 Category: Drugs & Pharmacology Source Type: research

HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals
AbstractHIV prevalence is elevated among transgender populations with an estimated 13.7% of transgender adults living with HIV in the USA. In addition, transgender people experience significant disparities in biomedical HIV prevention and treatment. The efficacy of topical microbicides for prevention of HIV acquisition have not been tested among transgender people and may be impacted by hormonal therapies and/or surgeries undertaken by some transgender people to align their anatomy with their gender identity. Low pre-exposure prophylaxis (PrEP) uptake and adherence as well as potential drug –hormone interactions impa...
Source: Drugs - May 25, 2020 Category: Drugs & Pharmacology Source Type: research

Functional Constipation: Individualising Assessment and Treatment
AbstractChronic constipation is one of the five most common symptoms seen by gastroenterologist. In the absence of alarm symptoms, a confident symptom-based diagnosis can often be made using the Rome criteria. Three different subtypes have been identified to date: normal transit constipation, defaecatory disorders and slow transit constipation. Differentiation between these subtypes can be made through functional testing using tests such as anorectal manometry with balloon expulsion and a radio-opaque marker test. In general, patients are initially advised to increase their fluid and fibre intake. When these general lifest...
Source: Drugs - May 25, 2020 Category: Drugs & Pharmacology Source Type: research

The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19
AbstractG-Quadruplexes (G4s) are non-canonical secondary structures formed within guanine-rich regions of DNA or RNA. G4 sequences/structures have been detected in human and in viral genomes, including Coronaviruses Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and SARS-CoV-2. Here, we outline the existing evidence indicating that G4 ligands and inhibitors of SARS-CoV-2 helicase may exert some antiviral activity reducing viral replication and can represent a potential therapeutic approach to tackle the COVID-19 pandemic due to SARS-CoV-2 infection. We also discuss how repositioning of FDA-approved drugs against ...
Source: Drugs - May 25, 2020 Category: Drugs & Pharmacology Source Type: research

Current Therapeutic Options for Controlled Ovarian Stimulation in Assisted Reproductive Technology
The objective of the present review is to provide an update on conventional ovarian stimulation, by giving an overview of treatment milestones, together with the latest innovations currently being investigated. The realization of an assisted reproduction technology treatment depends on many steps that can be medically manipulated and must be harmoniously combined, starting from the follicular phase and ending with luteal phase support. New technologies in the pharmaceutical sector are fundamental to optimize efficiency and tailor treatment approaches to individual needs. The present review aims to offer physicians a useful...
Source: Drugs - May 24, 2020 Category: Drugs & Pharmacology Source Type: research

Correction to: Isatuximab: First Approval
In the table ‘Key clinical trials of isatuximab (Sanofi)’, in the left-hand column. (Source: Drugs)
Source: Drugs - May 23, 2020 Category: Drugs & Pharmacology Source Type: research

Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer
AbstractPatients with oncogene-driven lung cancer have limited therapeutic options after progressing on their targeted tyrosine kinase inhibitor (TKI) therapy. Given the growing role of immune checkpoint inhibitor (ICI) therapy in the treatment of lung cancer, oncogene-driven cancer has warranted further evaluation regarding ICI therapy. However, initial ICI studies have suggested that ICI monotherapy is not only lacking in efficacy, but that it may be less tolerable in oncogene-driven non-small-cell lung cancer (NSCLC). We performed a detailed review of the literature using Pubmed, and present the current and impactful fi...
Source: Drugs - May 20, 2020 Category: Drugs & Pharmacology Source Type: research

Novel Approaches Towards a Functional Cure of HIV/AIDS
AbstractTherapeutic approaches towards a functional cure or eradication of HIV have gained renewed momentum upon encouraging data emerging from studies in SIV monkey models and recent results from human clinical studies. However, a multitude of questions remain to be addressed, including how to deal with the latent viral reservoir, how to boost the host immune response to the virus and what the hurdles are to reach relevant viral compartments in the body. Advances have been made especially with regard to identifying agents that can reactivate the latent virus in vivo and boost the cellular and humoral immunity, but it rema...
Source: Drugs - May 20, 2020 Category: Drugs & Pharmacology Source Type: research

Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT 2a Receptor Antagonists
AbstractAkathisia is one of the most prevalent and distressing adverse effects associated with antipsychotic drug treatment. Propranolol, a non-selective beta-adrenergic receptor antagonist, is currently considered a first-line treatment for antipsychotic-induced akathisia (AIA). Surprisingly, the evidence for its anti-akathisia effect is modest. Propranolol ’s side effects (e.g. orthostatic hypotension, bradycardia), contraindications (e.g. asthma) and increased complexity in titration schedules limit its use in some patients. Anticholinergic agents and benzodiazepines merely provide symptomatic relief in patients w...
Source: Drugs - May 8, 2020 Category: Drugs & Pharmacology Source Type: research

Ozanimod: First Approval
This article summarizes the milestones in the development of ozanimod leading to its first approval for relapsing forms of multiple sclerosis. (Source: Drugs)
Source: Drugs - May 8, 2020 Category: Drugs & Pharmacology Source Type: research

Tirabrutinib: First Approval
This article summarizes the milestones in the develo pment of tirabrutinib leading to the first approval of tirabrutinib for the treatment of recurrent or refractory primary central nervous system lymphoma in Japan. (Source: Drugs)
Source: Drugs - May 7, 2020 Category: Drugs & Pharmacology Source Type: research

Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson ’s Disease
AbstractParkinson ’s disease is a chronic, neurodegenerative disease, which manifests with a mixture of motor, cognitive and behavioural symptoms. Levodopa is the most effective antiparkinsonian treatment to date, although chronic use engenders a mixture of complications in a substantial proportion of patients. Amo ngst these is the occurrence of episodes of worsening symptoms—‘off’ phenomena. These episodes can manifest with either motor or non-motor symptoms or a combination of these features and have been found to have profound impacts on patients’ quality of life. Although preventative mea...
Source: Drugs - May 7, 2020 Category: Drugs & Pharmacology Source Type: research

Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach
AbstractRefractory rheumatoid arthritis (RA) has emerged as an area of unmet need in a landscape of generally well-controlled disease. Whilst most patients are adequately treated on methotrexate and other first-line disease-modifying anti-rheumatic drugs (DMARDs), a proportion requires biologic (b) and targeted synthetic (ts) DMARDs, with a further subsection failing multiple agents. Recent observational studies have adopted working definitions of refractory RA based on number of failed DMARDs, with prevalence estimates of 6 –21% depending on threshold and study population. Risk factors include treatment delay, basel...
Source: Drugs - May 2, 2020 Category: Drugs & Pharmacology Source Type: research

Tepotinib: First Approval
This article summarizes the milestones in the development of tepotinib leading to this first approval. (Source: Drugs)
Source: Drugs - May 2, 2020 Category: Drugs & Pharmacology Source Type: research

Uveitis Therapy: The Corticosteroid Options
AbstractUveitis is characterized by intraocular inflammation involving the uveal tract; its etiologies generally fall into two broad categories: autoimmune/inflammatory or infectious. Corticosteroids  are a powerful and important class of medications ubiquitous in the treatment of uveitis. They may be given systemically or locally, in the form of topical drops, periocular injection, intravitreal suspension, or intravitreal implant. This review describes each of the currently available corticost eroid treatment options for uveitis, including favorable and unfavorable characteristics of each as well as applicable clinic...
Source: Drugs - April 29, 2020 Category: Drugs & Pharmacology Source Type: research

Isatuximab: First Approval
This article summarizes the milestones in the development of isatuximab leading to the first approva l in the USA. (Source: Drugs)
Source: Drugs - April 28, 2020 Category: Drugs & Pharmacology Source Type: research

A New Paradigm for Achieving a Rapid Antidepressant Response
AbstractThe substantive delay (often 4 –6 weeks) between the commencement of an antidepressant and any discernible improvement in depressive symptoms is an ongoing concern in the management of depressive disorders. This delay incurs the risk of cessation of medication, self-harm/suicide and ongoing ‘damage’ to the brain caused by the illness. Both historically and now, off-label polypharmacy has been used in clinical practice in an attempt to facilitate both immediate- and long-term relief from symptoms. While somewhat effective, this strategy was unregulated and associated with severe adverse side e...
Source: Drugs - April 28, 2020 Category: Drugs & Pharmacology Source Type: research

ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3 –5: A Network Meta-Analysis of Randomised Clinical Trials
AbstractBackgroundThe advantages of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in reducing risk of cardiovascular events (CVEs) and delaying end-stage kidney disease (ESKD) in patients with chronic kidney disease (CKD) is well-known. However, the efficacy and safety of these agents in non-dialysis CKD  stages 3–5 patients are still a controversial issue.MethodsTwo investigators (Yaru Zhang and Dandan He) independently searched and identified relevant studies from MEDLINE (from 1950 to October 2018), EMBASE (from 1970 to October 2018), and the Cochrane Library data...
Source: Drugs - April 24, 2020 Category: Drugs & Pharmacology Source Type: research

New and Emerging Therapies for Alopecia Areata
AbstractAlopecia areata (AA) is an autoimmune condition that affects up to 2% of the general population. Currently available treatment options for AA are of limited efficacy and can be associated with adverse effects. The advancement in understanding of the genetic and molecular mechanisms of AA has led to the development of novel treatment options, with the Janus kinase (JAK) inhibitor class of drugs at the forefront of ongoing clinical trials. Platelet-rich plasma, fecal transplants, and cytokine-targeted therapy with ustekinumab and dupilumab have also been shown to regrow hair in patients with AA in individual case rep...
Source: Drugs - April 22, 2020 Category: Drugs & Pharmacology Source Type: research

Pharmacokinetics and Pharmacodynamics of Posaconazole
AbstractPosaconazole is typically used for preventing invasive yeast and mold infections such as invasive aspergillosis in high-risk immunocompromised patients. The oral suspension was the first released formulation and many pharmacokinetic and pharmacodynamic studies of this formulation have been published. Erratic absorption profiles associated with this formulation were widely reported. Posaconazole exposure was found to be significantly influenced by food and many gastrointestinal conditions, including pH and motility. As a result, low posaconazole plasma concentrations were obtained in large groups of patients. These ...
Source: Drugs - April 22, 2020 Category: Drugs & Pharmacology Source Type: research

Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
An Online First version of this article was made available online. (Source: Drugs)
Source: Drugs - April 22, 2020 Category: Drugs & Pharmacology Source Type: research

Levodopa Inhalation Powder: A Review in Parkinson ’s Disease
AbstractLevodopa inhalation powder (Inbrija®) is approved for the intermittent treatment of OFF episodes in patients with Parkinson ’s disease (PD) treated with levodopa/dopa-decarboxylase inhibitor (LD-DCI) in the EU and specifically with carbidopa/levodopa in the USA. The approved dosage is 84 mg taken as needed up to five times a day. Administered via a breath-actuated inhaler, this formulation enables levodopa to bypass t he gastrointestinal (GI) tract and, instead, rapidly enter the bloodstream through the pulmonary system. In the 12-week, double-blind, placebo-controlled, phase III SPAN-PD trial, ...
Source: Drugs - April 21, 2020 Category: Drugs & Pharmacology Source Type: research

Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
The article Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder, written by James E. Frampton, was originally published electronically in SpringerLink on 7 April 2020 without Open Access. After publication Alexion Pharmaceuticals, Inc., requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Alexion Pharmaceuticals, Inc. (Source: Drugs)
Source: Drugs - April 21, 2020 Category: Drugs & Pharmacology Source Type: research

Bempedoic Acid: First Approval
This article summarizes the milestones in the development of bempedoic acid leading to these first approvals. (Source: Drugs)
Source: Drugs - April 20, 2020 Category: Drugs & Pharmacology Source Type: research

Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma
AbstractCemiplimab (Libtayo®) is an antibody immunotherapy that stimulates an anti-cancer response via programmed cell death protein-1 (PD-1) blockade. It is the first approved treatment in the USA and EU for patients with locally advanced (laCSCC) or metastatic (mCSCC) cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiotherapy. Approval was based largely on positive results from the phase II EMPOWER-CSCC 1 trial in this patient population. In this pivotal trial, treatment with intravenous cemiplimab 3  mg/kg once every 2 weeks or 350 mg once every 3 weeks...
Source: Drugs - April 18, 2020 Category: Drugs & Pharmacology Source Type: research

New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
AbstractPancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at an advanced stage, with systemic therapy being the mainstay of treatment. Survival continues to be limited, typically less than 1  year. The PDAC microenvironment is characterized by a paucity of malignant epithelial cells, abundant stroma with predominantly immunosuppressive T cells and myelosuppressive-type macrophages (M2), and hypovascularity. The current treatment options for metastatic PDAC are modified (m)FOLFIRINOX /F OLFIRINOX or nab-paclitaxel and gemcitabine in patients with good performance status (PS) (ECOG 0-1/KPS 70-100%) and gemc...
Source: Drugs - April 18, 2020 Category: Drugs & Pharmacology Source Type: research

Potential for Harm Associated with Discharge Opioids After Hospital Stay: A Systematic Review
ConclusionThis systematic review suggests that the current discharge opioid prescribing practices can be improved. Lack of patient education regarding storage and disposal of opioids also contributes to the increasing rate of opioid misuse, diversion, and unintended long-term use. More high-quality research with comparable outcomes is needed. Evidence-based hospital guidelines and public health policies are needed to improve opioid stewardship. (Source: Drugs)
Source: Drugs - April 11, 2020 Category: Drugs & Pharmacology Source Type: research

Are Generic Drugs Used in Cardiology as Effective and Safe as their Brand-name Counterparts? A Systematic Review and Meta-analysis
ConclusionThe crude risk of hospital visits was higher for patients exposed to generic compared to brand-name cardiovascular drugs. However, the  evidence is insufficient and too heterogeneous to draw any firm conclusion regarding the effectiveness and safety of generic drugs in cardiology. (Source: Drugs)
Source: Drugs - April 11, 2020 Category: Drugs & Pharmacology Source Type: research

Remimazolam: First Approval
This article summarises the major milestones in the development of remimazolam for this first approval for the induction and maintenance of general anaesthesia, and its potential upcoming approvals in general anaesthesia and procedural sedation. (Source: Drugs)
Source: Drugs - April 9, 2020 Category: Drugs & Pharmacology Source Type: research

Rimegepant: First Approval
This article summarizes the milestones in the development of rimegepant leading to its first global approval for acute treatment of migraine (± aura) in adults. (Source: Drugs)
Source: Drugs - April 8, 2020 Category: Drugs & Pharmacology Source Type: research

Eptinezumab: First Approval
This article summarizes the milestones in the development of eptinezumab leading to this first approval. (Source: Drugs)
Source: Drugs - April 7, 2020 Category: Drugs & Pharmacology Source Type: research

Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
AbstractThe terminal complement protein (C5) inhibitor eculizumab (Soliris®) is the first agent to be specifically approved in the EU, USA, Canada and Japan for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 water channel autoantibody (AQP4-IgG) seropositive and (in the EU only) for those with a relapsing course of disease. In the phase III PREVENT trial, eculizumab significantly reduced the risk of adjudicated relapse relative to placebo in patients with AQP4-IgG-seropositive NMOSD, approximately a quarter of whom did not receive concomitant immunosuppressive therapies. T...
Source: Drugs - April 7, 2020 Category: Drugs & Pharmacology Source Type: research

Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer
AbstractAtezolizumab (Tecentriq®), an immune checkpoint inhibitor against programmed death ligand 1 (PD-L1), is the first immunotherapy agent to be approved (for use in combination with nab-paclitaxel) in the USA, the EU (as first-line) and Japan for the treatment of advanced triple-negative breast cancer (TNBC). Approval was based on the results of the phase III IMpassion130 trial in patients with unresectable locally advanced or metastatic TNBC, in which atezolizumab plus nab-paclitaxel significantly prolonged progression-free survival (PFS) when compared to placebo plus nab-paclitaxel in the intent-to-treat (ITT) po...
Source: Drugs - April 4, 2020 Category: Drugs & Pharmacology Source Type: research

Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps
AbstractDupilumab (Dupixent®) is a fully human IgG4 monoclonal antibody against the interleukin (IL)-4  receptor α (IL-4Rα) subunit, which is shared by the type I IL-4 and the type II IL-4/IL-13 receptor complexes. By binding to and blocking this subunit, dupilumab inhibits IL-4 and IL-13, which are the major drivers of human type 2 inflammatory disease [e.g. asthma, atopic dermatitis and chronic rhinosinusitis with nasal polyps (CRSwNP)]. Dupilumab, administered subcutaneously, is the first biological therapy to be approved for the treatment of adults with inadequately controlled CRSwNP in the EU and ...
Source: Drugs - April 2, 2020 Category: Drugs & Pharmacology Source Type: research

A Review of Management Strategies for Nociceptive and Neuropathic Ocular Surface Pain
AbstractDespite being a common presenting symptom to eye-care clinics, many ophthalmologists have difficulty diagnosing and managing ocular surface pain. The purpose of this review is to discuss potential causes of ocular surface pain, focusing on both nociceptive and neuropathic aetiologies. Specifically, we outline an approach to the diagnosis of ocular surface pain and focus on various management strategies, providing supporting evidence on the efficacy of various treatments. (Source: Drugs)
Source: Drugs - March 23, 2020 Category: Drugs & Pharmacology Source Type: research

Cenegermin: A Review in Neurotrophic Keratitis
AbstractCenegermin (Oxervate ™), an ophthalmic solution containing 20 µg/mL of recombinant human nerve growth factor (rhNGF), is the first drug to be approved for the treatment of neurotrophic keratitis (NK; also referred to as neurotrophic keratopathy). In the registration trials, the majority of adults with moderate or se vere NK experienced complete corneal healing after up to 8 weeks of topical cenegermin therapy. The rate of complete corneal healing was generally higher, and that of disease progression was lower, with cenegermin than with vehicle. Although the drug provided no statistically signi...
Source: Drugs - March 18, 2020 Category: Drugs & Pharmacology Source Type: research

Tislelizumab: First Approval
This article summarises the major milestones in the development of tislelizumab for this first approval for classical Hodgkin’s lymphoma, and its potential upcoming approvals in other indications. (Source: Drugs)
Source: Drugs - March 18, 2020 Category: Drugs & Pharmacology Source Type: research

Advances in Long-Acting Agents for the Treatment of HIV Infection
AbstractLong-acting antiretroviral therapy holds the promise of new options for human immunodeficiency virus (HIV) treatment beyond the current paradigm of daily oral pills. Of particular interest is their potential role in addressing challenges with adherence to oral therapy and treatment fatigue. Similar to other conditions where long-acting formulations have proven effective such as contraception and mental health, long-acting antiretroviral therapy could provide additional treatment choices to people with HIV. This review provides an outline of the current landscape of long-acting antiretroviral therapy for HIV treatme...
Source: Drugs - March 16, 2020 Category: Drugs & Pharmacology Source Type: research

Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances
AbstractErythrodermic psoriasis (EP) is an extreme and often refractory variant of psoriasis with high morbidity and increased mortality, and is frequently classified as a dermatological emergency. The pathophysiology of EP is largely unknown but is thought to differ from that of plaque psoriasis. Treatment of EP is challenging, and usually based on clinical experience and patient co-morbidities, due to its low incidence and limited clinical evidence. Conventional treatments, such as topical glucocorticoid therapy, cyclosporin, acitretin, and methotrexate have some but limited efficacy in EP, and treatment discontinuation ...
Source: Drugs - March 16, 2020 Category: Drugs & Pharmacology Source Type: research

Delgocitinib: First Approval
This article summarizes the milestones in the development of delgocitinib leading to this first approval for the treatment of adults with atopic dermatitis. Clinical development of the topical formulation is also underway for alopecia areata, chronic hand eczema, discoid lupus erythematosus, inverse psoriasis and atopic dermatitis in several countries worldwide. Clinical development of an oral formulation of delgocitinib is also underway in Japan for the treatment of autoimmune disorders and hypersensitivity. (Source: Drugs)
Source: Drugs - March 12, 2020 Category: Drugs & Pharmacology Source Type: research

Tazemetostat: First Approval
This article summarizes the milestones in the development of tazemetostat leading to this first approval for the treatment of adults and adolescents aged ≥ 16 years with locally advanced or metastatic epithelioid sarcoma not eligible for complete resection. (Source: Drugs)
Source: Drugs - March 12, 2020 Category: Drugs & Pharmacology Source Type: research

Correction to: Ubrogepant: First Approval
The article Ubrogepant: First Approval, written by Lesley J. Scott, was originally published published Online First without Open Access. After publication online Allergan Sales, LLC requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Allergan Sales, LLC. The article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate c...
Source: Drugs - March 12, 2020 Category: Drugs & Pharmacology Source Type: research

Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial
AbstractBackgroundMetformin is the first-line treatment for type 2 diabetes mellitus (T2DM), but many patients either cannot tolerate it or cannot achieve glycemic control with metformin alone, so treatment with other glucose-lowering agents in combination with metformin is frequently required. Remogliflozin etabonate, a novel agent, is an orally bioavailable prodrug of remogliflozin, which is a potent and selective sodium-glucose co-transporter-2 inhibitor.ObjectiveOur objective was to evaluate the efficacy and safety of remogliflozin etabonate compared with dapagliflozin in subjects with T2DM in whom a stable dose of met...
Source: Drugs - March 11, 2020 Category: Drugs & Pharmacology Source Type: research

Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments
AbstractIncreased hepatic glucose output, the primary liver dysregulation associated with Type 2 diabetes mellitus (T2DM), is not directly or effectively targeted by the currently available classes of glucose-lowering medications except metformin. This unmet need might be addressed through activation of a specific enzyme-member of the hexokinase family, namely glucokinase (GK). GK serves as a “glucose-sensor” or “glucose receptor” in pancreatic cells, eliciting glucose-stimulated insulin secretion, and as glucose “gate-keeper” in hepatocytes, promoting hepatic glucose uptake and glycogen...
Source: Drugs - March 11, 2020 Category: Drugs & Pharmacology Source Type: research

Teprotumumab: First Approval
This article summarizes the milestones in the development of teprotumumab leading to this first approval for thyroid eye disease. (Source: Drugs)
Source: Drugs - March 10, 2020 Category: Drugs & Pharmacology Source Type: research

Trastuzumab Deruxtecan: First Approval
This article summarizes the milestones in the development of trastuzumab deruxtecan leading to this first approval. (Source: Drugs)
Source: Drugs - March 7, 2020 Category: Drugs & Pharmacology Source Type: research

Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study
This study explored the patterns and risks of third-line ADD intensification post second-line ADDs and the probability of desirable glucose control over 12  months by third-line ADD classes at the population level.MethodsWe used the electronic medical records of 255,236 patients with T2DM in the USA initiating a second-line ADD post metformin from January 2013 to evaluate the rates and risks of third-line intensification and the probability of desirable glycemic control with different ADDs after addressing inherent heterogeneity using appropriate methodologies.ResultsPatients had a mean age of 60  years and glyca...
Source: Drugs - March 6, 2020 Category: Drugs & Pharmacology Source Type: research

Osilodrostat: First Approval
This article summarises the milestones in the development of osilodrostat leading to this first approval. (Source: Drugs)
Source: Drugs - March 5, 2020 Category: Drugs & Pharmacology Source Type: research